BirchBioMed | Anti-scarring | Auto-immune Therapeutics | Transplantation

Introducing BirchBioMed

BirchBioMed is a clinical-stage biomedical company
focused on the clinical evaluation, development and commercialization of anti-scarring drugs,
autoimmune therapeutics and novel strategies for transplantation.

POSITIVE TOPLINE DATA FROM PHASE 2 STUDY OF FS2
FOR TREATMENT OF KELOID SCARS

BirchBioMed Welcomes Dr. Jonathan Bourne as new Chief Science Officer

Positive Topline Data from Phase 2 Study of FS2 for Treatment of Keloid Scars

BirchBioMed appoints pharmaceutical leader and global affairs expert to its Board of Directors

BirchBioMed welcomes renowned dermatologist to its Board of Directors

Birch Issues Letter to Shareholders

First Patient Enrolled in BirchBioMed’s Study Investigating FS2 for the Treatment of Scars

BirchBioMed to Highlight FS2 Platform at the 17th Annual South Beach Symposium

BirchBioMed, Inc. to Present at the 11th Annual LD Micro Main Event

Sensus Healthcare CEO Joseph C. Sardano Joins BirchBioMed Inc. Board of Directors

Q&A with Mark S. Miller, Co-founder, Chairman and CEO of BirchBioMed Inc.

Birchbiomed Is Cleared To Begin First-of-its-kind Phase II Clinical Trial For Ground-Breaking Anti-Scarring Drug

Sensus Healthcare Launches Collaboration with BirchBioMed to Treat and Prevent Scarring for Keloids Patients Around the World

BirchBioMed’s Scientific Advisory Board Member Dr. Aziz Ghahary is the 2017 British Columbia Professional Fire Fighters Burn Fund Honouree

Birchbiomed announces completion of clinical trial for ground-breaking anti-scarring drug

UBC Develops Anti-scarring Drug

CKNW – Sean Leslie Show – Fibrostop, a Drug to Help Burn Victims

UBC researchers develop drug to treat scarring and autoimmune diseases…